Dr. Heinz Ludwig on the UVEA IXA Study

Background of the study:

In multiple myeloma treatment, it is important to improve our understanding of routine clinical practice and the effectiveness of new agents outside of clinical trials. Ixazomib (Ixa) is approved for MM patients (pts) who have received ≥1 prior therapy on the basis of TOURMALINE-MM1 study data.

In the video:

Dr. Heinz Ludwig (Wilhelminen Cancer Research Institute, Vienna, Austria) discusses the final analysis of UVEA IXA, which studies the efficacy and safety of ixazomib in relapsed/refractory patients outside of a clinical trial.

Conclusions:

UVEA-IXA data show that Ixa therapy is an effective, tolerable treatment option outside the clinical trial setting. Outcomes were favorable in pts with 1 vs ≥2 prior lines of therapy and ECOG PS 0–1 vs 2. Although UVEA-IXA data derive from retrospective chart review/infrequent prospective data capture and thus cannot be directly compared to clinical trial data, compared with TOURMALINE‑MM1 pts (Ixa arm; ORR 78%, mPFS 20.6 mos), UVEA-IXA pts had higher rates of ECOG PS 2 (20 vs 5%), ISS stage III multiple myeloma (30 vs 12%), and eGFR (epidermal Growth Factor Receptor) less than 30 mL/min (5 vs 1%), and had received more prior lines of therapy. Most common adverse events were gastrointestinal and hematologic, consistent with the safety profile in TOURMALINE-MM1.